Candel Therapeutics (CADL) News Today $6.02 +0.18 (+3.08%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$6.08 +0.06 (+1.00%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CADL Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of "Buy" from AnalystsAugust 10 at 3:47 AM | americanbankingnews.comWith 44% stake, Candel Therapeutics, Inc. (NASDAQ:CADL) seems to have captured institutional investors' interestAugust 8 at 4:41 AM | finance.yahoo.comCandel Therapeutics (CADL) Projected to Post Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comCandel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Rating of "Buy" from BrokeragesAugust 5, 2025 | marketbeat.comCandel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth ConferenceJuly 30, 2025 | globenewswire.comCandel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409July 24, 2025 | proactiveinvestors.comCandel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic CancerJuly 24, 2025 | globenewswire.comResearch Analysts Offer Predictions for CADL Q2 EarningsJuly 14, 2025 | marketbeat.comCandel Therapeutics, Inc. Gains Inclusion in Multiple Russell Value ...July 11, 2025 | nasdaq.comCandel Therapeutics, Inc. (NASDAQ:CADL) Given Average Recommendation of "Buy" by BrokeragesJuly 11, 2025 | marketbeat.comCandel Therapeutics (NASDAQ:CADL) Upgraded to "Strong-Buy" at Brookline Capital ManagementJuly 11, 2025 | marketbeat.comCandel Therapeutics expands Russell Index presence following 2025 reconstitutionJuly 9, 2025 | proactiveinvestors.comCandel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 ReconstitutionJuly 9, 2025 | globenewswire.comEquities Analysts Set Expectations for CADL Q3 EarningsJuly 1, 2025 | marketbeat.comCandel Therapeutics (NASDAQ:CADL) Receives "Buy" Rating from HC WainwrightJune 30, 2025 | marketbeat.comCADL - Candel Therapeutics Inc Ownership - MorningstarJune 28, 2025 | morningstar.comMOne Candel Therapeutics Insider Raised Stake By 22% In Previous YearJune 27, 2025 | finance.yahoo.comCandel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - NasdaqJune 26, 2025 | nasdaq.com2025-06-24 | Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock | NDAQ:CADL | Press ReleaseJune 26, 2025 | stockhouse.comCandel Therapeutics Inc News (CADL) - Investing.comJune 26, 2025 | investing.comCandel Therapeutics Appoints Charles Schoch as Chief Financial Officer - NasdaqJune 24, 2025 | nasdaq.comCandel Therapeutics prices 3.2M shares at $4.67 in registered direct offeringJune 24, 2025 | msn.comCandel Therapeutics announces $15M direct offering to support CAN-2409 launch preparationsJune 24, 2025 | proactiveinvestors.comCandel Therapeutics Announces $15 million Registered Direct Offering of Common StockJune 24, 2025 | globenewswire.comCandel Sinks on New CFOJune 23, 2025 | baystreet.caCandel Therapeutics names Charles Schoch as CFO after interim tenureJune 23, 2025 | proactiveinvestors.comCandel Therapeutics Appoints Charles Schoch as Chief Financial OfficerJune 23, 2025 | globenewswire.comBank of America Corp DE Buys 44,952 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)June 11, 2025 | marketbeat.comCandel Therapeutics adds biotech veteran Maha Radhakrishnan to BoardJune 6, 2025 | proactiveinvestors.comCandel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsJune 6, 2025 | globenewswire.comCandel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate CancerMay 30, 2025 | msn.comCandel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On?May 28, 2025 | benzinga.comCandel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term BuyMay 28, 2025 | msn.comCandel Therapeutics get FDA's RMAT designation for prostate cancer therapyMay 28, 2025 | proactiveinvestors.comCandel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate CancerMay 28, 2025 | globenewswire.comCandel Therapeutics: CAN-2409's Promising Progress Deserves An UpgradeMay 27, 2025 | seekingalpha.comCandel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO PresentationMay 27, 2025 | globenewswire.comCandel’s phase 3 trial for prostate cancer therapy shows promiseMay 24, 2025 | investing.comCandel Therapeutics to Present Positive Phase 3 Clinical Trial Results of CAN-2409 for Prostate Cancer at ASCO 2025May 24, 2025 | nasdaq.comCandel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025May 23, 2025 | proactiveinvestors.comCandel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025May 23, 2025 | insidermonkey.comCandel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025May 22, 2025 | globenewswire.comMaven Securities LTD Invests $449,000 in Candel Therapeutics, Inc. (NASDAQ:CADL)May 16, 2025 | marketbeat.comCandel Therapeutics (NASDAQ:CADL) Announces Quarterly Earnings Results, Beats Expectations By $0.37 EPSMay 15, 2025 | marketbeat.comCardell Flat on Q1May 13, 2025 | baystreet.caCandel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More BullishMay 13, 2025 | msn.comCandel Therapeutics posts Q1 profit, eyes 2026 BLA submission for prostate cancer drugMay 13, 2025 | proactiveinvestors.comCandel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsMay 13, 2025 | globenewswire.comCandel Therapeutics (CADL) Expected to Announce Earnings on TuesdayMay 8, 2025 | marketbeat.comBraidwell LP Invests $13.89 Million in Candel Therapeutics, Inc. (NASDAQ:CADL)May 8, 2025 | marketbeat.com Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address CADL Media Mentions By Week CADL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CADL News Sentiment▼0.510.50▲Average Medical News Sentiment CADL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CADL Articles This Week▼43▲CADL Articles Average Week Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CVAC News Today CALT News Today NTLA News Today HROW News Today PRAX News Today AVDL News Today PAHC News Today PHVS News Today ARDX News Today GPCR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CADL) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
